Advertisement

Topics

Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients

2014-08-27 03:45:31 | BioPortfolio

Summary

The purpose of this study is to monitor a specific cellular immune response in melanoma patients at an early stage of the disease, that have been vaccinated with a Melan-A VLP vaccine.

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Intervention Model: Single Group Assignment, Masking: Open Label

Conditions

Malignant Melanoma

Intervention

CYT004-MelQbG10

Location

Centre Pluridisciplinaire d'Oncologie & LICR, CHUV
Lausanne
Vaude
Switzerland
1011

Status

Completed

Source

Cytos Biotechnology AG

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:45:31-0400

Clinical Trials [1368 Associated Clinical Trials listed on BioPortfolio]

Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients

The purpose of this study is to evaluate a specific cellular immune response in melanoma patients that have been vaccinated with a Melan-A VLP vaccine alone or in combination with differen...

Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients

The purpose of this study is to evaluate a specific cellular immune response in melanoma patients that have been vaccinated with a Melan-A VLP vaccine.

Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients

The purpose of this study is to evaluate whether vaccination with a Melan-A VLP vaccine leads to a specific cellular immune response in patients with malignant melanoma at advanced stage o...

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

The purpose of this research study is to find out whether JX-594 is safe and effective for treating surgically unresectable malignant melanoma.

The Identification of Novel Prognostic Markers in Melanoma

The purpose of this project is to analyze tumour tissue from a group of subjects with malignant melanoma, who have been treated at the Royal Marsden Hospital.

PubMed Articles [2467 Associated PubMed Articles listed on BioPortfolio]

Clinical outcomes of primary intracranial malignant melanoma and metastatic intracranial malignant melanoma.

Primary intracranial malignant melanoma (PIMM) is extremely rare central nervous system (CNS) tumor and known for only composed 0.07% of the CNS tumors. PIMM composed only 1% of malignant melanoma and...

Primary malignant melanoma of the female urethra: Report of a rare neoplasm of the urinary tract.

Melanoma is a malignant tumor that can affect any area of the anatomical economy. Its occurance in the female urethra is extremely rare. We report a case of primary malignant urethral melanoma develop...

A review of primary malignant melanoma arising in an ovarian cystic teratoma.

Primary malignant melanoma arising in an ovarian cystic teratoma is exceedingly rare event with an estimated incidence of 0.2-0.8%. So far, there have been approximately only 47 relevant reports. We r...

Rare germline variants in known melanoma susceptibility genes in familial melanoma.

Known high-risk cutaneous malignant melanoma (CMM) genes account for melanoma risk in 

Primary Malignant Melanoma in the Pineal Region: Case Report and Literature Review.

 Primary pineal malignant melanoma is a rare type of primary central nervous system melanoma with only 19 cases reported in the literature.

Medical and Biotech [MESH] Definitions

An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin. (Dorland, 27th ed; Stedman, 25th ed)

Tumors of the iris characterized by increased pigmentation of melanocytes. Iris nevi are composed of proliferated melanocytes and are associated with neurofibromatosis and malignant melanoma of the choroid and ciliary body. Malignant melanoma of the iris often originates from preexisting nevi.

A cellular subtype of malignant melanoma. It is a pigmented lesion composed of melanocytes occurring on sun-exposed skin, usually the face and neck. The melanocytes are commonly multinucleated with a "starburst" appearance. It is considered by many to be the in situ phase of lentigo maligna melanoma.

Found in large amounts in the plasma and urine of patients with malignant melanoma. It is therefore used in the diagnosis of melanoma and for the detection of postoperative metastases. Cysteinyldopa is believed to be formed by the rapid enzymatic hydrolysis of 5-S-glutathionedopa found in melanin-producing cells.

Clinically atypical nevi (usually exceeding 5 mm in diameter and having variable pigmentation and ill defined borders) with an increased risk for development of non-familial cutaneous malignant melanoma. Biopsies show melanocytic dysplasia. Nevi are clinically and histologically identical to the precursor lesions for melanoma in the B-K mole syndrome. (Stedman, 25th ed)

More From BioPortfolio on "Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Searches Linking to this Trial